Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 33 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. BCL2 Inhibitor Venetoclax With Daratumumab-Lenalidomide-Dexamethasone Or Venetoclax-Rd for Newly Diagnosed Multiple Myeloma

    Rochester, MN

  2. KTX-100 MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma

    La Crosse, WI, Rochester, MN

  4. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    Jacksonville, FL

  5. Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel

    Rochester, MN

  6. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

  7. American Society of Hematology Research Collaborative’s Data Hub Multiple Myeloma Program

    Rochester, MN

  8. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)

    Rochester, MN

  9. The Impact of a Geriatric Assessment in Elderly Patients with Multiple Myeloma

    Rochester, MN

  10. A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements.

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer